[1]JournalofMedicinalChemistry,2007,vol.50,p.233-240
[1]JournalofMedicinalChemistry,2007,vol.50,p.233-240
[1]JournalofMedicinalChemistry,2007,vol.50,p.233-240
[1]JournalofMedicinalChemistry,2007,vol.50,p.233-240
[1]JournalofMedicinalChemistry,2007,vol.50,p.233-240
Title: Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Journal: Psychopharmacology 20120201
Title: Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
Journal: Psychopharmacology 20110301
Title: Reduced cAMP, Akt activation and p65-c-Rel dimerization: mechanisms involved in the protective effects of mGluR3 agonists in cultured astrocytes.
Journal: PloS one 20110101
Title: LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100701
Title: Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor.
Journal: Synapse (New York, N.Y.) 20091001
Title: Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Journal: The Journal of pharmacology and experimental therapeutics 20080701
Title: Glutamate agonists for schizophrenia stimulate dopamine D2High receptors.
Journal: Schizophrenia research 20080201
Title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Journal: Nature medicine 20070901
Title: In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Journal: Psychopharmacology 20070701
Title: Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Journal: The Journal of pharmacology and experimental therapeutics 20070401
Title: Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
Journal: Journal of medicinal chemistry 20070125
Title: Linda M Rorick-Kehn, et al. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo.1.0-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 2007 Apr;321(1):308-17.
Title: Seeman P. An agonist at glutamate and dopamine D2 receptors, LY404039. Neuropharmacology. 2013 Mar;66:87-8.
Title: Rorick-Kehn LM, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonistLY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl). 2007 Jul;193(1):121-36.
